Since the development of DNA recombinant technology in E. coli by H. Boyer and S. Cohen in 1973, tremendous progresses have been made until now. Cells that produce proteins have been expanded from bacteria to insects, plants and animals and the carriers have also become diversified from plasmid to bacteriophage, insect virus, animal virus and transcriptome (mRNA), etc. Recently, it has become possible to manufacture protein with cell-free synthesis system. Only the highly pure proteins are guaranteed after having subjected the manufactured protein to purification procedures with numerous stages. Protein with biological activity can be packaged into the final product after the evaluation by the biological activity assay.

Protein is the highlighted substance in the therapeutics market. All of the protein therapeutics, cytokines therapeutics, antibody therapeutics and vaccine, etc. are composed of proteins. Unlike the synthetic chemical therapeutics, it is sold as a highly priced therapeutics due to the necessity for a highly advanced manufacturing technology.

JW CreaGene is pursuing researches, development, manufacturing and sales of antigens, cytokine and cell growth factors by having established E. coli manifestation system and insect manifestation system, and excellent purification system. JW CreaGene shall deduced innovative items and pursues their commercialization as marketable products on the basis of the outstanding and highly professional manpower and protein technology the company is equipped with.